| P2093 | author name string | Joshua A Boyce | |
| | Tanya M Laidlaw | |
| | Katherine N Cahill | |
| | Jillian C Bensko | |
| P2860 | cites work | Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand | Q28287399 |
| | Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor | Q28371781 |
| | Characterization of the human cysteinyl leukotriene 2 receptor | Q30305734 |
| | Mast cells are required for experimental oral allergen-induced diarrhea | Q33630242 |
| | The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations | Q34403411 |
| | Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans | Q34597967 |
| | Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma | Q35563238 |
| | Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. | Q35858061 |
| | Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes | Q37240446 |
| | Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells | Q37691114 |
| | Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites | Q38013046 |
| | PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? | Q39664542 |
| | Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses | Q41864224 |
| | Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. | Q42826850 |
| | Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease | Q42950579 |
| | Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge | Q43069043 |
| | Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. | Q45986027 |
| | Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma | Q46363432 |
| | Prostaglandin D₂ induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. | Q50789916 |
| | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. | Q51091863 |
| | The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. | Q54471386 |
| | Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma | Q59685326 |
| | Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps | Q67596561 |
| | Urinary Leukotriene E4Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects | Q67915846 |
| | Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction | Q69304770 |
| | Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma | Q70578946 |
| | Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry | Q70648774 |
| | Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges | Q71214039 |
| | Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans | Q71728205 |
| | Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics | Q71906913 |
| | The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma | Q72204968 |
| | Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2 | Q72283615 |
| | Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma | Q72964940 |
| | Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma | Q74289995 |
| | Interaction of PGH synthase isozymes-1 and -2 with nonsteroidal anti-inflammatory drugs | Q74454826 |
| | Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism | Q77400152 |
| | Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses | Q78247441 |
| | Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients | Q85510369 |
| | Characterization of the human cysteinyl leukotriene CysLT1 receptor | Q22010199 |
| | Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 | Q24290855 |
| | Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits | Q24563352 |
| | Molecular cloning and expression of human leukotriene-C4 synthase | Q24563556 |
| | Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4 | Q24564369 |
| | The safety of celecoxib in patients with aspirin-sensitive asthma | Q28193684 |
| | A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge | Q28195706 |
| | Effect of leukotriene modifier drugs on the safety of oral aspirin challenges | Q28212449 |
| | Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity | Q28217507 |
| | Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper | Q28219101 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| P304 | page(s) | 245-252 | |
| P577 | publication date | 2014-09-11 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease | |
| P478 | volume | 135 | |